Recently the Endocrine Society published a new clinical practice guideline entitled, “Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.” What exactly is hypercalcemia of malignancy? What are its symptoms? How is it treated? And what do the guidelines recommend? To help answer these questions, host Aaron Lohr talks with Ghada El-Hajj Fuleihan, MD, MPH, professor of medicine at the American University in Beirut in Lebanon. She is the chair of the Society working group that developed this guideline. For helpful links or to hear more podcast epis ..read more

In this episode, host Aaron Lohr discusses screening, diagnosis, and current and emerging treatment options for the long-term management of growth hormone deficiency in pediatric and adult patients with Dr. Mark E. Molitch, MD, Professor Emeritus of Medicine, Northwestern University Feinberg School of Medicine. In addition, Dr. Molitch gives listeners a four-question quiz at the end. Remember to pause in between the question and answer! This episode is certified for up to 0.5 American Medical Association Physician’s Recognition Award (AMA PRA) Category 1 credits and American Board of Internal ..read more

The Endocrine Society made news recently by launching a new, online-only, open-access journal called , which is dedicated to clinical cases in endocrinology. What can we learn from case studies, and what does this journal have to offer? To answer those questions, host Aaron Lohr talks with Editor-in-Chief William F. Young Jr., MD, the Tyson Family Endocrinology Clinical Professor and professor of medicine in the Mayo Clinic College of Medicine at Mayo Clinic in Rochester, Minn. For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podc ..read more

In this episode, host Aaron Lohr looks back at the Endocrine Society’s Type 1 Diabetes Fellows Conference, which occurred last year, with two conference presenters talking about developmental challenges in type 1 diabetes, including psychological and social, across the lifespan. Our guests are Linda Siminerio, PhD, professor of medicine at University of Pittsburgh and executive director of the university’s Diabetes Institute, and Jill Weissberg-Benchell, PhD, professor of psychiatry and behavioral sciences at Northwestern University. Dr. Siminerio’s presentation was titled, “Identifying and Co ..read more

We look at Vosoritide, a promising, potential treatment for children with genetic short stature who do not have chondrodysplasia. Host Aaron Lohr talks with Andrew Dauber, MD, division chief of endocrinology at Children’s National Hospital. Dr. Dauber and colleagues presented about Vosoritide at ENDO 2022. Their abstract is titled, “A Prospective Clinical Trial of Vosoritide in Selected Genetic Causes of Short Stature.” For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast ..read more

Endocrine-disrupting chemicals are pretty much everywhere, and all of us have some level of exposure. Today we will talk about research presented at ENDO 2022 on a group of EDCs called parabens. The title of that abstract is “Parabens Promote Pro-Tumorigenic Effects in Luminal Breast Cancer Cell Lines With Diverse Genetic Ancestry.” Host Aaron Lohr talks with one of the authors of that study, Lindsey Treviño, PhD, assistant professor at City of Hope National Medical Center. They talk not just about the effects of parabens as an EDC, but also about racial and ethnic disparities in risk and mort ..read more

In this episode, we talk about an exciting experimental treatment for patients with type 1 diabetes called islet cell transplantation. Host Aaron Lohr talks with David Baidal, MD, assistant professor of medicine at the University of Miami Miller School of Medicine. This episode is made possible through an unrestricted, educational grant from Vertex Pharmaceuticals. For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast ..read more

We know how helpful continuous glucose monitors are for individuals with diabetes, but might they be of benefit to individuals with prediabetes? Today host Aaron Lohr will talk with Hisham Farhan, MD, an endocrinology fellow at the University of Maryland Medical Center. Dr. Farhan and colleagues made an oral presentation at ENDO 2022 titled, “Impact of Continuous Glucose Monitoring (CGM) on Lifestyle Modifications in Individuals with Prediabetes.” For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast ..read more

Fructose is sweeter than glucose and is often added to processed foods as a sweetener, commonly in the form of high-fructose corn syrup. Some studies suggest that fructose consumption may be associated with nonalcoholic fatty liver disease, and some new research, recently presented at ENDO, addresses this issue. Host Aaron Lohr talks with one of the authors of this research, Theodore Friedman, MD, PhD, chairman of internal medicine at Charles R. Drew University of Medicine & Science and professor of medicine at University of California, Los Angeles. Dr. Friedman and colleagues’ oral presen ..read more

Today we shine a spotlight on a fascinating area of focus within endocrinology that maybe you haven't heard much about: oncoendocrinology. What is it, and how are health providers working together to care for patients who have endocrine conditions and cancer? Host Aaron Lohr talks with Afreen I. Shariff, MD, an endocrinologist at Duke University School of Medicine with expertise in endocrine disease in cancer patients. Dr. Shariff is the founding director of the Duke Endocrine-Oncology Program and an associate director for the Cancer Treatment Toxicity Program at the Duke Center for Cancer Imm ..read more